FR2970967B1 - Derives de type azaindazole ou diazaindazole comme medicament - Google Patents

Derives de type azaindazole ou diazaindazole comme medicament

Info

Publication number
FR2970967B1
FR2970967B1 FR1150651A FR1150651A FR2970967B1 FR 2970967 B1 FR2970967 B1 FR 2970967B1 FR 1150651 A FR1150651 A FR 1150651A FR 1150651 A FR1150651 A FR 1150651A FR 2970967 B1 FR2970967 B1 FR 2970967B1
Authority
FR
France
Prior art keywords
diazaindazole
azaindazole
derivatives
medicinal product
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1150651A
Other languages
English (en)
French (fr)
Other versions
FR2970967A1 (fr
Inventor
El Bachir Kaloun
Karim Bedjeguelal
Remi Rabot
Anna Kruczynski
Philippe Schmitt
Michel Perez
Nicolas Rahier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR1150651A priority Critical patent/FR2970967B1/fr
Priority to TW101102531A priority patent/TWI546303B/zh
Priority to NZ614432A priority patent/NZ614432B2/en
Priority to JP2013550886A priority patent/JP5931926B2/ja
Priority to EP12701884.4A priority patent/EP2668184B1/en
Priority to MYPI2013002799A priority patent/MY180666A/en
Priority to LTEP12701884.4T priority patent/LT2668184T/lt
Priority to PCT/EP2012/051283 priority patent/WO2012101239A1/en
Priority to MX2013008673A priority patent/MX356411B/es
Priority to RS20180418A priority patent/RS57101B1/sr
Priority to RU2013138624/04A priority patent/RU2600976C2/ru
Priority to HK13114261.8A priority patent/HK1186737B/xx
Priority to CA2823824A priority patent/CA2823824C/en
Priority to ES12701884.4T priority patent/ES2661695T3/es
Priority to BR112013018852-9A priority patent/BR112013018852B1/pt
Priority to SI201231273T priority patent/SI2668184T1/en
Priority to PL12701884T priority patent/PL2668184T3/pl
Priority to HRP20180524TT priority patent/HRP20180524T1/hr
Priority to HUE12701884A priority patent/HUE037153T2/hu
Priority to MA36177A priority patent/MA34903B1/fr
Priority to PT127018844T priority patent/PT2668184T/pt
Priority to KR1020187031264A priority patent/KR20180122028A/ko
Priority to CN201280006671.8A priority patent/CN103339129B/zh
Priority to UAA201310425A priority patent/UA109698C2/ru
Priority to AU2012210467A priority patent/AU2012210467B2/en
Priority to KR1020137022330A priority patent/KR101923751B1/ko
Priority to ARP120100272A priority patent/AR084935A1/es
Priority to US13/823,658 priority patent/US20130172360A1/en
Priority to DK12701884.4T priority patent/DK2668184T3/en
Priority to TR2018/02944T priority patent/TR201802944T4/tr
Publication of FR2970967A1 publication Critical patent/FR2970967A1/fr
Priority to US13/686,334 priority patent/US8883821B2/en
Application granted granted Critical
Publication of FR2970967B1 publication Critical patent/FR2970967B1/fr
Priority to TNP2013000293A priority patent/TN2013000293A1/fr
Priority to IL227496A priority patent/IL227496B/en
Priority to IL257748A priority patent/IL257748B/en
Priority to CY20181100338T priority patent/CY1120088T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR1150651A 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament Active FR2970967B1 (fr)

Priority Applications (35)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
TW101102531A TWI546303B (zh) 2011-01-27 2012-01-20 氮雜吲唑（ａｚａｉｎｄａｚｏｌｅ）或二氮雜吲唑（ｄｉａｚａｉｎｄａｚｏｌｅ）類型之衍生物供作藥物之用途
PT127018844T PT2668184T (pt) 2011-01-27 2012-01-27 Derivados do tipo azaindazole ou diazaindazole utilizados como medicamentos
EP12701884.4A EP2668184B1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
MYPI2013002799A MY180666A (en) 2011-01-27 2012-01-27 Substituted pyrazolo [3,4-b] pyridines as medicaments
LTEP12701884.4T LT2668184T (lt) 2011-01-27 2012-01-27 Azaindazolo arba diazaindazolo tipo dariniai kaip vaistai
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
MX2013008673A MX356411B (es) 2011-01-27 2012-01-27 Derivados del tipo del azaindazol o diazaindazol como medicamento.
RS20180418A RS57101B1 (sr) 2011-01-27 2012-01-27 Derivati tipa azaindazola ili diazaindazola kao lek
RU2013138624/04A RU2600976C2 (ru) 2011-01-27 2012-01-27 Производные азаиндазола или диазаиндазола в качестве медикамента
CN201280006671.8A CN103339129B (zh) 2011-01-27 2012-01-27 作为药物的氮杂吲唑或二氮杂吲唑类衍生物
CA2823824A CA2823824C (en) 2011-01-27 2012-01-27 Derivatives of azaindazoles and diazaindazoles and their use as medicaments
ES12701884.4T ES2661695T3 (es) 2011-01-27 2012-01-27 Derivados de tipo azaindazol o diazaindazol como medicamento
BR112013018852-9A BR112013018852B1 (pt) 2011-01-27 2012-01-27 Derivados do tipo azaindazol ou diazaindazol, seus usos na preparação de fármacos, métodos de preparação dos mesmos, e composições farmacêuticas compreendendo os referidos compostos
SI201231273T SI2668184T1 (en) 2011-01-27 2012-01-27 PRODUCTS OF AZAINDAZOL OR DIAZAINDAZOL AS A MEDICINAL PRODUCT
PL12701884T PL2668184T3 (pl) 2011-01-27 2012-01-27 Pochodne typu azaindazolu lub diazaindazolu jako lek
HRP20180524TT HRP20180524T1 (hr) 2011-01-27 2012-01-27 Derivati tipa azaindazola ili diazaindazola kao lijek
HUE12701884A HUE037153T2 (hu) 2011-01-27 2012-01-27 Azaindazol vagy diazaindazol típusú származékok mint gyógyszerek
NZ614432A NZ614432B2 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
KR1020187031264A KR20180122028A (ko) 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체
JP2013550886A JP5931926B2 (ja) 2011-01-27 2012-01-27 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体
HK13114261.8A HK1186737B (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
UAA201310425A UA109698C2 (xx) 2011-01-27 2012-01-27 Похідні азаіндазолу або діазаіндазолу як медикамент
AU2012210467A AU2012210467B2 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
KR1020137022330A KR101923751B1 (ko) 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체
ARP120100272A AR084935A1 (es) 2011-01-27 2012-01-27 Derivados de tipo azaindazol o diazaindazol como medicamentos
US13/823,658 US20130172360A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
DK12701884.4T DK2668184T3 (en) 2011-01-27 2012-01-27 DERIVATIVES OF AZAINDAZOL OR DIAZAINDAZOL TYPE AS MEDICATION
TR2018/02944T TR201802944T4 (tr) 2011-01-27 2012-01-27 İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
MA36177A MA34903B1 (fr) 2011-01-27 2012-01-27 Derives de type azaindazole ou diazaindazole utilises comme medicaments
US13/686,334 US8883821B2 (en) 2011-01-27 2012-11-27 Substituted pyrazolo[3,4-b]pyridines as medicaments
TNP2013000293A TN2013000293A1 (en) 2011-01-27 2013-07-11 Derivatives of azaindazole or diazaindazole type as medicament
IL227496A IL227496B (en) 2011-01-27 2013-07-16 Pyrazolo[4,3–b]pyridines are converted as drugs
IL257748A IL257748B (en) 2011-01-27 2018-02-26 Derivatives of pyrazole [4,3-b]pyridine, pyrazolo[4,3-b]pyridine and pyrazolo[4,3-b]pyrazine for use in the treatment of cancer, inflammatory diseases and neurodegenerative diseases,
CY20181100338T CY1120088T1 (el) 2011-01-27 2018-03-26 Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου ως φαρμακo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament

Publications (2)

Publication Number Publication Date
FR2970967A1 FR2970967A1 (fr) 2012-08-03
FR2970967B1 true FR2970967B1 (fr) 2013-02-15

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1150651A Active FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament

Country Status (30)

Country Link
US (2) US20130172360A1 (OSRAM)
EP (1) EP2668184B1 (OSRAM)
JP (1) JP5931926B2 (OSRAM)
KR (2) KR20180122028A (OSRAM)
CN (1) CN103339129B (OSRAM)
AR (1) AR084935A1 (OSRAM)
AU (1) AU2012210467B2 (OSRAM)
BR (1) BR112013018852B1 (OSRAM)
CA (1) CA2823824C (OSRAM)
CY (1) CY1120088T1 (OSRAM)
DK (1) DK2668184T3 (OSRAM)
ES (1) ES2661695T3 (OSRAM)
FR (1) FR2970967B1 (OSRAM)
HR (1) HRP20180524T1 (OSRAM)
HU (1) HUE037153T2 (OSRAM)
IL (2) IL227496B (OSRAM)
LT (1) LT2668184T (OSRAM)
MA (1) MA34903B1 (OSRAM)
MX (1) MX356411B (OSRAM)
MY (1) MY180666A (OSRAM)
PL (1) PL2668184T3 (OSRAM)
PT (1) PT2668184T (OSRAM)
RS (1) RS57101B1 (OSRAM)
RU (1) RU2600976C2 (OSRAM)
SI (1) SI2668184T1 (OSRAM)
TN (1) TN2013000293A1 (OSRAM)
TR (1) TR201802944T4 (OSRAM)
TW (1) TWI546303B (OSRAM)
UA (1) UA109698C2 (OSRAM)
WO (1) WO2012101239A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
BR112014020773A2 (pt) 2012-02-22 2020-10-27 Sanford-Burnham Medical Research Institute compostos de sulfonamida e seus usos como inibidores tnap
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US20220259199A1 (en) * 2018-05-02 2022-08-18 Jw Pharmaceutical Corporation Novel heterocycle derivative
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
JP2023509421A (ja) * 2019-12-31 2023-03-08 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115916771B (zh) * 2020-04-02 2025-04-01 浙江华海药业股份有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
CA3198342A1 (en) 2020-11-20 2022-05-27 Patric T. Gunning Benzenesulfonamide derivatives and uses thereof
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2283961A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
HUP0301183A3 (en) 2000-06-22 2006-02-28 Pfizer Process for the preparation of pyrazolopyrimidinones
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
KR101011957B1 (ko) * 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
SI2120932T1 (sl) 2006-12-20 2014-09-30 Nerviano Medical Sciences S.R.L. Indazolni derivati kot kinazni inhibitorji za zdravljenje raka
PL2176231T3 (pl) 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Podstawione pochodne indazolu aktywne jako inhibitory kinazy
EP2373626B1 (en) 2008-12-18 2016-08-24 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Also Published As

Publication number Publication date
CA2823824A1 (en) 2012-08-02
IL257748A (en) 2018-04-30
TWI546303B (zh) 2016-08-21
PT2668184T (pt) 2018-03-13
AU2012210467B2 (en) 2016-07-07
TN2013000293A1 (en) 2015-01-20
WO2012101239A1 (en) 2012-08-02
KR101923751B1 (ko) 2018-11-29
FR2970967A1 (fr) 2012-08-03
IL257748B (en) 2020-06-30
CA2823824C (en) 2018-12-11
EP2668184A1 (en) 2013-12-04
JP2014503574A (ja) 2014-02-13
UA109698C2 (xx) 2015-09-25
AU2012210467A1 (en) 2013-09-12
NZ614432A (en) 2015-03-27
TW201247664A (en) 2012-12-01
CN103339129A (zh) 2013-10-02
HK1186737A1 (en) 2014-03-21
CY1120088T1 (el) 2018-12-12
LT2668184T (lt) 2018-04-10
US20130172360A1 (en) 2013-07-04
BR112013018852A2 (pt) 2017-08-15
IL227496A0 (en) 2013-09-30
MX356411B (es) 2018-05-24
BR112013018852B1 (pt) 2021-12-21
ES2661695T3 (es) 2018-04-03
MY180666A (en) 2020-12-04
SI2668184T1 (en) 2018-06-29
DK2668184T3 (en) 2018-03-12
US8883821B2 (en) 2014-11-11
IL227496B (en) 2019-02-28
HRP20180524T1 (hr) 2018-05-04
RS57101B1 (sr) 2018-06-29
EP2668184B1 (en) 2018-01-10
KR20180122028A (ko) 2018-11-09
US20130085144A1 (en) 2013-04-04
TR201802944T4 (tr) 2018-03-21
MA34903B1 (fr) 2014-02-01
CN103339129B (zh) 2015-07-29
MX2013008673A (es) 2013-12-02
JP5931926B2 (ja) 2016-06-08
PL2668184T3 (pl) 2018-06-29
RU2600976C2 (ru) 2016-10-27
KR20140014147A (ko) 2014-02-05
AR084935A1 (es) 2013-07-10
HUE037153T2 (hu) 2018-08-28
RU2013138624A (ru) 2015-03-10

Similar Documents

Publication Publication Date Title
FR2970967B1 (fr) Derives de type azaindazole ou diazaindazole comme medicament
ZA201406968B (en) Soft chewable pharmaceutical product
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
DK3501558T3 (da) Flydbare vævsprodukter
EP2858630A4 (en) Nanotherapeutics for drug targeting
BR112014012778A2 (pt) embalagem de cateter
EP2568979A4 (en) RATIOMETRIC COMBINATORY MEDICINE ADMINISTRATION
EP2695621A4 (en) PHARMACEUTICAL PREPARATION
CL2014003283A1 (es) Formulación farmacéutica.
BR112014015885A2 (pt) preparação farmacêutica
IL231622B (en) Pharmaceutical composition for treatment of cachexia
EP2720707A4 (en) INFLAMMATORY PHARMACEUTICAL PRODUCTS
EP2668186A4 (en) PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES
EP2671578A4 (en) PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PERIPHERAL NEUROPATHY CAUSED BY AN ANTICANCER AGENT
DK3473255T3 (da) Farmaceutisk formulering omfattende ciclesonid
ZA201405925B (en) Pharmaceutical formulation having improved stability
BR302012006318S1 (pt) Configuração aplicada em vaporizador de produtos fluidos
GB201206384D0 (en) Antibacterial drug derivatives
EP2668185A4 (en) PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES
HUE049344T2 (hu) Gyermekgyógyászati készítmény
BR302012006320S1 (pt) Configuração aplicada em vaporizador de produtos fluidos
GB201222679D0 (en) Pharmaceutical combination products
AU2012265231A1 (en) Nasal pharmaceutical formulation
IT1399867B1 (it) Inserto illustrativo per medicinali.
GB201206385D0 (en) Antibacterial drug derivatives

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15